DUBLIN, August 17, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Acute Coronary Syndrome: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
The $1.9bn acute coronary syndrome (ACS) market will experience moderate growth over the forecast period, driven by uptake of Brilinta and Xarelto in the secondary-prevention setting.
This report addresses the following questions:
- How will the updated 2016 treatment guidelines impact the use of new antiplatelet agents Effient and Brilinta?
- How will Brilinta's label expansion impact its sales within ACS?
- How will Xarelto's expected US approval in ACS affect its patient share in comparison to generic warfarin?
- What are the most commonly prescribed therapies for ACS in the acute and secondary-prevention treatment settings?
- What are the most important factors influencing prescribing trends in ACS?
Key Topics Covered:
FORECAST: ACUTE CORONARY SYNDROME
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Angiomax (bivalirudin)
- Brilinta (ticagrelor)
- Effient (prasugrel)
- Kengreal (cangrelor)
- Plavix (clopidogrel)
- Xarelto (rivaroxaban)
- Zontivity (vorapaxar)
- Primary Research Methodology
TREATMENT: ACUTE CORONARY SYNDROME
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Prescribing Trends
EPIDEMIOLOGY: ACUTE CORONARY SYNDROME IN THE US, JAPAN, AND 5EU
- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Co-Morbidities
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography
MARKETED DRUGS: ACUTE CORONARY SYNDROME
- Executive Summary
- Product Overview
- Product profile: Angiomax
- Product profile: Brilinta
- Product profile: Effient
- Product profile: Kengreal
- Product profile: Plavix
- Product profile: Xarelto
- Product profile: Zontivity
For more information about this report visit http://www.researchandmarkets.com/research/tqdmkb/acute_coronary
Related Topics: Cardiovascular Drugs
Media Contact:
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article